The global contract packaging organization Tjoapack is announcing an expansion of its contract packaging and cold chain storage services in both the United States and The Netherlands (1). The company intends to scale its logistics infrastructure to meet rising demand it has seen for injectables and biologics, as well as bolster its supply chain resilience and deliver faster turnaround times and greater flexibility for clients.
In a press release on June 5, 2025, Tjoapack detailed the changes planned for the facilities in Clinton, Tenn., in the US, and at Etten-Leur in The Netherlands.
Improvements coming online soon
Key Takeaways
- Tjoapack is expanding packaging and cold chain services in the US and EU to support growing demand for biologics, injectables, and self-administered therapies.
- New automated lines in Clinton, Tenn., will enable high-throughput vial and auto-injector packaging with integrated traceability, labeling, and serialization.
- Etten-Leur now offers fully automated prefilled syringe packaging, as both sites scale cold storage to maintain GMP standards across temperature-sensitive products.
At the Clinton site, Tjoapack is completing installation of two advanced packaging lines that will support high-throughput, sterile packaging operations (1). A line expected to be completed in the second quarter of 2025 is high-speed and fully automated for vial packaging, with an annual processing capability of 20 million vials—including integrated labeling, cartooning, and serialization. In the third quarter, a semi-automated auto-injector line that offers end-to-end traceability and labeling will be scheduled for qualification. Cold storage capacity at this site has been expanded and validated, providing a total of 160 good manufacturing practice-compliant pallet spaces in controlled 2–8°C conditions.
The Etten-Leur facility has also seen its cold chain capacity increase, bringing on 84 additional pallet spaces to push its total to 120, under the same temperature guidelines. This site, according to Tjoapack, additionally has completed its first commercial project for prefilled syringe (PFS) packaging (1). The fully automated PFS line offers syringe assembly with or without safety devices, automated plunger rod insertion, and insertion of ancillary components like needles, among other features.
“These upgrades directly address the accelerating needs of our clients in the biologics and sterile injectable space,” said Dexter Tjoa, CEO of Tjoapack, in the press release (1). “We are committed to building scalable, compliant infrastructure that ensures the efficient delivery of vital therapies without compromising on flexibility or quality. By strengthening its injectable packaging and cold chain capabilities, Tjoapack is supporting a wider range of primary container formats, including vials, ampoules, syringes, and auto-injectors, while scaling capacity to better serve both new and existing clients across North America and Europe.”